Brief Report| Volume 62, ISSUE 1, P34-38, January 2013

Download started.


A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance



      Insulin resistance (IR) is associated with low adiponectin and elevated high sensitivity C-reactive protein (hsCRP). Osteoprotegerin (OPG) has been shown to be elevated in type 2 diabetes, but whether it reflects underlying IR is unclear. We aimed to compare the ability of serum OPG with adiponectin and hsCRP to act as a marker for IR in individuals with normal and abnormal glucose tolerance.


      115 men underwent a 75 g oral glucose tolerance test. OPG, hsCRP and adiponectin were measured using ELISA. IR was assessed using the homeostasis model assessment of insulin resistance (HOMA-IR).


      Men with abnormal glucose tolerance (n=38) were older (58.3±11.2 vs 47.3±11.4 years, P<.001), had higher body mass index (BMI) (31.1±2.9 vs 27.9±3.2 kg/m2, P<.001) and were more insulin resistant (median (I.Q.) HOMA-IR 5.88 (3.38) vs 1.13 (1.14), P<.001) than those with normal glucose tolerance (n=77). After adjustment for age and BMI, OPG (6.28 (2.32) vs 5.16 (1.86) pmol/L, P<.001) and hsCRP (2.07 (5.47) vs 0.78 (1.05) mg/L, P<.001) were higher and adiponectin (3.02±1.17 vs 4.78±2.38 μg/mL, P<.001) was lower in those with AGT. After adjustment for age and BMI, adiponectin (r=0.317, P<.001) and hsCRP (r=0.318, P<.001), but not OPG (r=0.126, P=.196) correlated with HOMA-IR. On multiple linear regression analysis, adiponectin and hsCRP but not OPG were independent predictors of HOMA-IR.


      OPG is higher in individuals with abnormal glucose tolerance, but unlike adiponectin and hsCRP, does not correlate with HOMA-IR, suggesting its elevation within this cohort of individuals is due to factors other than insulin resistance.


      hsCRP (high sensitivity C-reactive protein), OPG (Osteoprotegerin), HOMA-IR (homeostatic model assessment of insulin resistance), IR (insulin resistance), NGT (normal glucose), OGTT (oral glucose tolerance test), AUC (Area under the curve), ACE (angiotensin converting enzyme), ARB (inhibitor, angiotensin receptor blocker)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. DeFronzo, R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270–87.

        • Pfutzner A.
        • Forst T.
        High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
        Diabetes Technol Ther. 2006; 8: 28-36
        • Matsuzawa Y.
        Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease.
        Atheroscler Suppl. 2005; 6: 7-14
        • Simonet W.S.
        • Lacey D.L.
        • Dunstan C.R.
        • Kelley M.
        • Chang M.S.
        • Luthy R.
        • et al.
        Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
        Cell. 1997; 89: 309-319
        • Tsuda E.
        • Goto M.
        • Mochizuki S.
        • Yano K.
        • Kobayashi F.
        • Morinaga T.
        • et al.
        Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
        Biochem Biophys Res Commun. 1997; 234: 137-142
        • Jono S.
        • Ikari Y.
        • Shioi A.
        • Mori K.
        • Miki T.
        • Hara K.
        • et al.
        Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.
        Circulation. 2002; 106: 1192-1194
        • Knudsen S.T.
        • Foss C.H.
        • Poulsen P.L.
        • Andersen N.H.
        • Mogensen C.E.
        • Rasmussen L.M.
        Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications.
        Eur J Endocrinol. 2003; 149: 39-42
        • O'Sullivan E.P.
        • Ashley D.T.
        • Davenport C.
        • Devlin N.
        • Crowley R.
        • Agha A.
        • et al.
        Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
        Diabetes Metab Res Rev. 2010; 26: 496-502
        • Kim S.M.
        • Lee J.
        • Ryu O.H.
        • Lee K.W.
        • Kim H.Y.
        • Seo J.A.
        • et al.
        Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity.
        Clin Endocrinol (Oxf). 2005; 63: 594-598
        • Akinci B.
        • Celtik A.
        • Yuksel F.
        • Genc S.
        • Yener S.
        • Secil M.
        • et al.
        Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome.
        Diabetes Res Clin Pract. 2011; 91: 26-31
        • Federation, W.H.O.I.D.
        Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : report of a WHO/IDF consultation. 2006
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • Naylor B.A.
        • Treacher D.F.
        • Turner R.C.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Gannage-Yared M.H.
        • Yaghi C.
        • Habre B.
        • Khalife S.
        • Noun R.
        • Germanos-Haddad M.
        • et al.
        Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study.
        Eur J Endocrinol. 2008; 158: 353-359
        • Yaturu S.
        • Rains J.
        • Jain S.K.
        Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.
        Cytokine. 2008; 44: 168-171
        • Pepene C.E.
        • Ilie I.R.
        • Marian I.
        • Duncea I.
        Circulating osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
        Eur J Endocrinol. 2011; 164: 61-68
        • Ashley D.T.
        • O'Sullivan E.P.
        • Davenport C.
        • Devlin N.
        • Crowley R.K.
        • McCaffrey N.
        • et al.
        Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
        Metabolism. 2011; 60: 994-1000
        • Ugur-Altun B.
        • Altun A.
        • Gerenli M.
        • Tugrul A.
        The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity.
        Diabetes Res Clin Pract. 2005; 68: 217-222
        • Ugur-Altun B.
        • Altun A.
        Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women.
        Arch Med Res. 2007; 38: 891-896
        • Hofso D.
        • Ueland T.
        • Hager H.
        • Jenssen T.
        • Bollerslev J.
        • Godang K.
        • et al.
        Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose.
        Eur J Endocrinol. 2009; 161: 451-458
        • Sodi R.
        • Hazell M.J.
        • Durham B.H.
        • Rees C.
        • Ranganath L.R.
        • Fraser W.D.
        The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism.
        Clin Biochem. 2009; 42: 1375-1380
        • Carnevale V.
        • Romagnoli E.
        • D'Erasmo E.
        Skeletal involvement in patients with diabetes mellitus.
        Diabetes Metab Res Rev. 2004; 20: 196-204